Journal of Hematology & Oncology (Aug 2023)

Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia

  • Waled Bahaj,
  • Tariq Kewan,
  • Carmelo Gurnari,
  • Arda Durmaz,
  • Ben Ponvilawan,
  • Ishani Pandit,
  • Yasuo Kubota,
  • Olisaemeka D. Ogbue,
  • Misam Zawit,
  • Yazan Madanat,
  • Taha Bat,
  • Suresh K. Balasubramanian,
  • Hussein Awada,
  • Ramsha Ahmed,
  • Minako Mori,
  • Manja Meggendorfer,
  • Torsten Haferlach,
  • Valeria Visconte,
  • Jaroslaw P. Maciejewski

DOI
https://doi.org/10.1186/s13045-023-01480-y
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background TP53 mutations (TP53 MT ) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly leukemogenic, questioning the presence of cryptic biallelic subclones in cases with dismal prognosis. Methods We have collected clinical and molecular data of 7400 patients with myeloid neoplasms and applied a novel model by identifying an optimal VAF cutoff using a statistically robust strategy of sampling-based regression on survival data to accurately classify the TP53 allelic configuration and assess prognosis more precisely. Results Overall, TP53 MT were found in 1010 patients. Following the traditional criteria, 36% of the cases were classified as single hits, while 64% exhibited double hits genomic configuration. Using a newly developed molecular algorithm, we found that 579 (57%) patients had unequivocally biallelic, 239 (24%) likely contained biallelic, and 192 (19%) had most likely monoallelic TP53 MT . Interestingly, our method was able to upstage 192 out of 352 (54.5%) traditionally single hit lesions into a probable biallelic category. Such classification was further substantiated by a survival-based model built after re-categorization. Among cases traditionally considered monoallelic, the overall survival of those with probable monoallelic mutations was similar to the one of wild-type patients and was better than that of patients with a biallelic configuration. As a result, patients with certain biallelic hits, regardless of the disease subtype (AML or MDS), had a similar prognosis. Similar results were observed when the model was applied to an external cohort. In addition, single-cell DNA studies unveiled the biallelic nature of previously considered monoallelic cases. Conclusion Our novel approach more accurately resolves TP53 genomic configuration and uncovers genetic mosaicism for the use in the clinical setting to improve prognostic evaluation.

Keywords